1074-59-5

Usage

Uses

Used in Pharmaceutical Industry:
3-(IMIDAZOL-4-YL)PROPIONIC ACID is used as a pharmaceutical intermediate for the synthesis of various drug candidates. Its imidazole and propionic acid moieties provide a foundation for the development of compounds with potential therapeutic effects, particularly in the treatment of neurological disorders and other conditions.
Used in Chemical Research:
In the field of chemical research, 3-(IMIDAZOL-4-YL)PROPIONIC ACID serves as a key building block for the creation of novel chemical entities. Its unique structure allows for the exploration of new chemical reactions and the synthesis of innovative molecules with potential applications in various industries.
Used in Material Science:
3-(IMIDAZOL-4-YL)PROPIONIC ACID is utilized in material science for the development of new materials with specific properties. Its imidazole ring can participate in coordination chemistry, making it a candidate for the design of coordination polymers and other advanced materials with applications in catalysis, sensing, and energy storage.

InChI:InChI=1/C6H8N2O2/c9-6(10)2-1-5-3-7-4-8-5/h3-4H,1-2H2,(H,7,8)(H,9,10)

Upstream product

• 6736-42-1 3-(2-thioxo-2,3-dihydro-1H-imidazol-4-yl)-acrylic acid 
• 31434-93-2 methyl 3-(4-imidazolyl)propionate 
• 3465-72-3 urocanic Acid 
• 104-98-3 4-imidazoleacrylic acid 
• 3465-72-3 (E)-3-(1H-imidazol-4-yl)propenoic acid 
• 104-98-3 urocanic acid 
• 50-00-0 formaldehyd 
• 71-00-1 L-histidine 
• 71-00-1 D,L-histidine 
• 4708-67-2 3-(2-thioxo-2,3-dihydro-1H-imidazol-4-yl)-propionic acid 

Downstream Products

• 52237-38-4 ethyl 3-(imidazol-4'-yl)-propanoate 
• 160446-35-5 3-(1H-1-triphenylmethylimidazol-4-yl)propanoic acid 
• 1159884-24-8 3-(1H-imidazol-4-yl)-N-(3-(5-(2-((4-morpholin-4-ylphenyl)amino)pyrimidin-4-yl)imidazo[2,1-b][1,3]thiazol-6-yl)phenyl)propanamide 
• 52237-38-4 ethyl 3-imidazol-4⁽⁵⁾-ylpropanoate 
• 31434-93-2 methyl 3-(1H-imidazol-5-yl)propanoate 
• 209599-09-7 4-but-3-ynyl-1-(triphenylmethyl)imidazole 
• 102676-61-9 3-(1-triphenylmethyl-4-imidazolyl)propionaldehyde 
• 1271376-54-5 1-(3-(1H-imidazol-4-yl)propyl)-4-(2-cyclohexylethyl)-1H-1,2,3-triazole 
• 1271376-52-3 1-(3-(1H-imidazol-4-yl)propyl)-4-cyclohexyl-1H-1,2,3-triazole 
• 1271376-46-5 VUF 10192 
• 31434-93-2 methyl 3-(4-imidazolyl)propionate 
• 53958-94-4 3-(1H-imidazol-4-yl)propionic acid methyl ester hydrochloride 
• 113872-16-5 3-(1(3)H-imidazol-4-yl)-propionic acid hydrazide 
• 126377-28-4 [2-(3,4-Dimethoxy-phenyl)-ethyl]-[3-(1H-imidazol-4-yl)-propyl]-amine 

Relevant academic research and scientific papers

Structure based design of novel inhibitors for histidinol dehydrogenase from Geotrichum candidum

Histidinol dehydrogenase, the product of the HisD gene, mediates the final step in the histidine biosynthetic pathway. This enzyme has captured attention for drug discovery studies in past few years. Recently, our group cloned and expressed Geotrichum candidum histidinol dehydrogenase and successful screening of substrate analog inhibitors of histidinol dehydrogenase led to some antifungal compounds with IC50 values in micromolar range. In this study, we have done docking analysis of these antifungal agents in G. candidum. Two new compounds were designed based on the docking results and these compounds turned out to be potent inhibitors of G. candidum histidinol dehydrogenase, showing IC50 values as low as 3.17 μM.

SMALL MOLECULE VE-PTP INHIBITORS

The present disclosure relates to compounds capable of inhibiting vascular endothelial protein tyrosine phosphatase (VE-PTP). These compounds are also capable of activating Tie2 receptor-mediated signaling. The present disclosure also relates to pharmaceutically acceptable salts of said compounds, to pharmaceutical compositions comprising such compounds and/or pharmaceutically acceptable salts thereof, and to the use of such compounds, pharmaceutically acceptable salts thereof, and/or pharmaceutical compositions comprising the same in treating diseases and/or conditions mediated by VE-PTP signaling, such as those mediated by Angiopoietm/Tie2 signaling.

AMIDE COMPOUNDS, METHODS FOR PREPARATION, AND USE THEREOF AS AGENTS FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY RNA- AND/OR DNA-CONTAINING VIRUSES, AND CONCOMITANT DISEASES

The present invention relates to medicine and includes a method for preventing and treating diseases caused by RNA- and DNA-containing viruses, and concomitant diseases, wherein the method comprises the use of an effective amount of compounds of general formula I or pharmaceutically acceptable salts thereof. The invention also relates to methods for preparing said compounds, pharmaceutical compositions for the prevention or treatment of diseases caused by RNA- and DNA-containing viruses, said compositions comprising an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof. The invention addresses the object of providing a novel agent effective in the treatment of diseases caused by an RNA-containing virus belonging to the Enterovirus, Metapneumovirus, Pneumovirus, Respirovirus, or Alfa-coronavirus genus, and/or by a DNA-containing virus belonging to the Adenoviridae and/or Herpesviridae family, and in the prevention and treatment of asthma exacerbation, chronic obstructive pulmonary disease, mucoviscidosis, conjunctivitis, gastroenteritis, hepatitis, myocarditis; in the prevention and treatment of rhinorrhea, acute and infectious rhinitis, pharyngitis, nasopharyngitis, tonsillitis, laryngitis, laryngotracheitis, laryngotracheobronchitis, bronchitis, bronchiolitis, pneumonia, or airway obstructive syndrome.

Triazole ligands reveal distinct molecular features that induce histaine H4 receptor affinity and subtly govern H4/H3 subtype selectivity

The histamine H3 (H3R) and H4 (H 4R) receptors attract considerable interest from the medicinal chemistry community. Given their relatively high homology yet widely differing therapeutic promises, ligand selectivity for the two receptors is crucial. We interrogated H4R/H3R selectivities using ligands with a [1,2,3]triazole core. Cu(I)-assisted "click chemistry" was used to assemble diverse [1,2,3]triazole compounds (6a-w and 7a-f), many containing a peripheral imidazole group. The imidazole ring posed some problems in the click chemistry putatively due to Cu(II) coordination, but Boc protection of the imidazole and removal of oxygen from the reaction mixture provided effective strategies. Pharmacological studies revealed two monosubstituted imidazoles (6h,p) with 4R affinities and >10-fold H 4R/H3R selectivity. Both compounds possess a cycloalkylmethyl group and appear to target a lipophilic pocket in H 4R with high steric precision. The use of the [1,2,3]triazole scaffold is further demonstrated by the notion that simple changes in spacer length or peripheral groups can reverse the selectivity toward H3R. Computational evidence is provided to account for two key selectivity switches and to pinpoint a lipophilic pocket as an important handle for H4R over H3R selectivity.

COMPOUND WITH ANTIMALARIAL ACTIVITY AND ANTIMALARIAL DRUG CONTAINING THE SAME AS ACTIVE INGREDIENT

Compounds with high antimalarial activity; and antimalarial drugs containing the same as an active ingredient. There are provided compounds with antimalarial activity represented by the chemical formula: (wherein R1 is H, Cl or OCH3; R2 is H or CH3; R3 is CH, CH2, C(CH3), CH(CH3) or C(CH3)2; Ar is imidazole, triazole, pyridine, benzene, pyrrole, furan, thiophene or derivatives thereof; n is 1 to 5; and m is 1 to 5). Further, there are provided antimalarial drugs containing these compounds with antimalarial activity or pharmacologically acceptable salts thereof as active ingredients.

Chemokine receptor binding heterocyclic compounds with enhanced efficacy

The invention relates to heterocyclic compounds consisting of a core nitrogen atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolyl methyl and tetrahydroquinolyl, and the third pendant group contains N and optionally contains additional rings. The compounds bind to chemokine receptors, including CXCR4 and CCR5, and demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).

Prenyl transferase inhibitors

A family of imidazole compounds useful for inhibiting the activity of prenyl transferases. The compounds are covered by the following formula: wherein X is (CHR11)n3(CH2)n4Z(CH2)n5 where Z is O, N(R12), S, or a bond; Y is CO, CH2, CS, or a bond; R1 is or N(R24R23); and the remaining substituents are as defined in the disclosure.

Chemokine receptor binding heterocyclic compounds with enhanced efficacy

The invention relates to heterocyclic compounds consisting of a core nitrogen atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolyl methyl and tetrahydroquinolyl, and the third pendant group contains N and optionally contains additional rings. The compounds bind to chemokine receptors, including CXCR4 and CCR5, and demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).

A novel series of (phenoxyalkyl)imidazoles as potent H3-receptor histamine antagonists

[[(4-Nitrophenyl)X]alkyl]imidazole isosteres (where X = NH, S, CH2S, O) of previously described [[(5-nitropyrid-2-yl)X]ethyl]imidazoles (where X = NH, S) have been synthesized and evaluated for H3-receptor histamine antagonism in vitro (K(i) for [3H]histamine release from rat cerebral cortex synaptosomes) and in vivo (ED50 per os in mice on brain tele- methylhistamine levels). Encouraging results led to the synthesis and testing of a novel series of substituted (phenoxyethyl)- and (phenoxypropyl)imidazoles. From the latter, 4-[3-(4-cyanophenoxy)propyl]-1H- imidazole (10a, UCL 1390; K(i) = 12 nM, ED50 = 0.54 mg/kg) and 4-[3-[4- (trifluoromethyl)-phenoxy]propyl]-1H-imidazole (10c, UCL 1409; K(i) = 14 nM, ED50 = 0.60 mg/kg) have been selected as potential candidates for drug development. For 16 [(aryloxy)ethyl]imidazoles the relationship between in vitro and in vivo potency is described by the equation log ED50 = 0.47 log K(i) + 0.20 (r = 0.78).

Novel 1,2,4-oxadiazoles as potent and selective histamine H3 receptor antagonists

Replacement of the isothiourea moiety of known histamine H3 antagonists by certain 5-membered heteroaromatic systems can give compounds with an improved activity profile. One of these, 3-[(4-chlorophenyl)methyl]-5-[2-(1H-imidazol-4-yl)ethyl] 1,2,4-oxadiazole (GR175737) is a potent, selective, orally active and centally penetrating H3 antagonist.